Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MSAugust 28, 2014Multiple Sclerosis
Clinical and Subclinical Factors Strongly Influence MS Treatment DecisionsAugust 28, 2014Multiple Sclerosis
Ofatumumab Reduces New Gadolinium-Enhancing Lesions With Partial B Cell DepletionJune 26, 2014Multiple Sclerosis
High BMI and Weight in Young Adulthood Are Linked to Younger Age of MS Symptom OnsetJune 25, 2014Multiple Sclerosis
Brain and Cognitive Reserve May Protect Against Cognitive Decline in MSJune 25, 2014Multiple Sclerosis
